Cost-effectiveness of influenza vaccination in high-risk children in Argentina

被引:30
|
作者
Dayan, GH
Nguyen, VH
Debbag, R
Gómez, R
Wood, SC
机构
[1] Fdn Ctr Estudios Infectol, Buenos Aires, DF, Argentina
[2] Aventis Pasteur, Buenos Aires, DF, Argentina
[3] Biogen Europe, Paris, France
关键词
influenza; vaccination; cost-effectiveness;
D O I
10.1016/S0264-410X(01)00160-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: our study aimed to evaluate the cost-effectiveness of influenza vaccination in high-risk children in Argentina. Methods: a decision analysis model was performed, using data from published and unpublished sources. to compare two strategies - to vaccinate or not to vaccinate. We simulated the expected consequences of vaccination on direct medical costs, related to disease management and indirect costs, related to lost parental working days (absenteeism). Results: Using base-case assumptions vaccination of high-risk children aged 6 months to 15 years old, in Argentina (estimated cohort of 1184748) would prevent 207331 cases of influenza, resulting in a reduction of 58052 days of hospitalization and 207331 outpatient visits. Vaccination would lead to net savings of US$ 11894870 per vaccinated cohort (US$ 10.04 per vaccinated child). Conclusion: our economic analysis shows that in Argentina, routine vaccination of high-risk children against influenza would be cost saving for society. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:4204 / 4213
页数:10
相关论文
共 50 条
  • [21] Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination
    Quinn, Emma
    Jit, Mark
    Newall, Anthony T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (03) : 425 - 435
  • [22] Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability
    Anthony T. Newall
    Juan Pablo Dehollain
    Prudence Creighton
    Philippe Beutels
    James G. Wood
    PharmacoEconomics, 2013, 31 : 693 - 702
  • [23] Seasonal influenza vaccination of high-risk adults
    Loubet, Paul
    Loulergue, Pierre
    Galtier, Florence
    Launay, Odile
    EXPERT REVIEW OF VACCINES, 2016, 15 (12) : 1507 - 1518
  • [24] The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
    de Boer, Pieter T.
    Kelso, Joel K.
    Haider, Nilimesh
    Thi-Phuong-Lan Nguyen
    Moyes, Jocelyn
    Cohen, Cheryl
    Barr, Ian G.
    Postma, Maarten J.
    Milne, George J.
    VACCINE, 2018, 36 (07) : 997 - 1007
  • [25] Influenza vaccination in children with high-risk chronic diseases YY
    Hatziagorou, Elpis
    Argyropoulou, Evangelia
    Soldatou, Alexandra
    Tsanakas, John
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [26] Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany
    Scholz, Stefan M.
    Weidemann, Felix
    Damm, Oliver
    Ultsch, Bernhard
    Greiner, Wolfgang
    Wichmann, Ole
    VALUE IN HEALTH, 2021, 24 (01) : 32 - 40
  • [27] Cost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Plan
    Morales-Zamora, Gilberto
    Espinosa, Oscar
    Puertas, Edwin
    Fernandez, Juan Carlos
    Hernandez, Jose
    Zakzuk, Veronica
    Cepeda, Magda
    Alvis-Guzman, Nelson
    Castaneda-Orjuela, Carlos
    Paternina-Caicedo, Angel
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 31 : 101 - 110
  • [28] Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the UK
    Meier, G.
    Gregg, M.
    Nautrup, B. Poulsen
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (09) : 746 - 761
  • [29] Cost-effectiveness of norovirus vaccination in children in Peru
    Mirelman, Andrew J.
    Ballard, Sarah Blythe
    Saito, Mayuko
    Kosek, Margaret N.
    Gilman, Robert H.
    VACCINE, 2015, 33 (27) : 3084 - 3091
  • [30] Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age
    Marchetti, Monia
    Kuehnel, Ursula M.
    Colombo, Giorgio L.
    Esposito, Susanna
    Principi, Nicola
    HUMAN VACCINES, 2007, 3 (01): : 14 - 22